NASDAQ:ALXO ALX Oncology Q2 2026 Earnings Report $1.70 -0.04 (-2.30%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$1.69 -0.01 (-0.59%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ALX Oncology EPS ResultsActual EPS-$0.13Consensus EPS -$0.14Beat/MissBeat by +$0.01One Year Ago EPSN/AALX Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AALX Oncology Announcement DetailsQuarterQ2 2026Date8/6/2026TimeBefore Market OpensConference Call DateThursday, August 6, 2026Conference Call Time8:00AM ETUpcoming EarningsALX Oncology's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ALX Oncology Earnings HeadlinesALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by AnalystsSeptember 9, 2026 | americanbankingnews.comALX Oncology to Present at Upcoming Investor Conferences in SeptemberSeptember 2, 2026 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 20 at 1:00 AM | Stansberry Research (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)August 8, 2026 | theglobeandmail.comALX Oncology Holdings Earnings Estimates, EPS & Revenue | NASDAQ:ALXO | BenzingaJuly 7, 2026 | benzinga.comALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesJune 30, 2026 | globenewswire.comSee More ALX Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALX Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALX Oncology and other key companies, straight to your email. Email Address About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company focused on developing therapies that activate the immune system to fight cancer. The company’s approach targets the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid being identified and destroyed by macrophages and other immune cells. ALX Oncology’s lead product candidate is evorpacept, formerly known as ALX148. Evorpacept is an investigational fusion protein designed to block the CD47 “don’t eat me” signal while limiting the binding of normal blood cells. The company has evaluated evorpacept in combination with other cancer treatments, including antibody therapies, across multiple solid-tumor and hematologic cancer settings. The company’s clinical development programs have included studies in head and neck cancer, gastric and gastroesophageal-junction cancer, and other oncology indications. ALX Oncology is headquartered in South San Francisco, California, and has pursued clinical development through collaborations and trials involving research centers and patients in the United States and other regions. As a clinical-stage biotechnology company, its products remain investigational and are not approved for commercial use.View ALX Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
